vs
Side-by-side financial comparison of Claritev Corp (CTEV) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $246.6M, roughly 1.4× Claritev Corp). HAEMONETICS CORP runs the higher net margin — 13.2% vs -32.7%, a 45.9% gap on every dollar of revenue. On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $36.4M). Over the past eight quarters, Claritev Corp's revenue compounded faster (2.5% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CTEV vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $339.0M |
| Net Profit | $-80.6M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | -3.1% | 19.9% |
| Net Margin | -32.7% | 13.2% |
| Revenue YoY | 6.2% | -2.7% |
| Net Profit YoY | 41.6% | 19.3% |
| EPS (diluted) | $-4.88 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $339.0M | ||
| Q3 25 | $246.0M | $327.3M | ||
| Q2 25 | $241.6M | $321.4M | ||
| Q1 25 | $231.3M | $330.6M | ||
| Q4 24 | $232.1M | $348.5M | ||
| Q3 24 | $230.5M | $345.5M | ||
| Q2 24 | $233.5M | $336.2M | ||
| Q1 24 | $234.5M | — |
| Q4 25 | $-80.6M | $44.7M | ||
| Q3 25 | $-69.8M | $38.7M | ||
| Q2 25 | $-62.6M | $34.0M | ||
| Q1 25 | $-71.3M | $58.0M | ||
| Q4 24 | $-138.0M | $37.5M | ||
| Q3 24 | $-391.4M | $33.8M | ||
| Q2 24 | $-576.7M | $38.4M | ||
| Q1 24 | $-539.7M | — |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% | ||
| Q1 24 | — | — |
| Q4 25 | -3.1% | 19.9% | ||
| Q3 25 | 4.1% | 17.9% | ||
| Q2 25 | 6.9% | 16.8% | ||
| Q1 25 | 4.2% | 21.6% | ||
| Q4 24 | -17.8% | 16.9% | ||
| Q3 24 | -146.7% | 15.0% | ||
| Q2 24 | -224.4% | 11.8% | ||
| Q1 24 | -207.4% | — |
| Q4 25 | -32.7% | 13.2% | ||
| Q3 25 | -28.4% | 11.8% | ||
| Q2 25 | -25.9% | 10.6% | ||
| Q1 25 | -30.8% | 17.5% | ||
| Q4 24 | -59.4% | 10.8% | ||
| Q3 24 | -169.8% | 9.8% | ||
| Q2 24 | -247.0% | 11.4% | ||
| Q1 24 | -230.1% | — |
| Q4 25 | $-4.88 | $0.95 | ||
| Q3 25 | $-4.23 | $0.81 | ||
| Q2 25 | $-3.81 | $0.70 | ||
| Q1 25 | $-4.38 | $1.17 | ||
| Q4 24 | $-8.49 | $0.74 | ||
| Q3 24 | $-24.25 | $0.66 | ||
| Q2 24 | $-35.78 | $0.74 | ||
| Q1 24 | $-33.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $363.4M |
| Total DebtLower is stronger | $4.6B | $1.2B |
| Stockholders' EquityBook value | $-173.9M | $911.5M |
| Total Assets | $4.9B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $363.4M | ||
| Q3 25 | $39.2M | $296.4M | ||
| Q2 25 | $56.4M | $292.9M | ||
| Q1 25 | $23.1M | $306.8M | ||
| Q4 24 | $16.8M | $320.8M | ||
| Q3 24 | $86.6M | $299.3M | ||
| Q2 24 | $48.8M | $344.4M | ||
| Q1 24 | $58.7M | — |
| Q4 25 | $4.6B | $1.2B | ||
| Q3 25 | $4.5B | $1.2B | ||
| Q2 25 | $4.5B | $1.2B | ||
| Q1 25 | $4.5B | $1.2B | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $-173.9M | $911.5M | ||
| Q3 25 | $-101.8M | $849.2M | ||
| Q2 25 | $-39.9M | $882.3M | ||
| Q1 25 | $14.8M | $820.8M | ||
| Q4 24 | $84.0M | $906.9M | ||
| Q3 24 | $207.6M | $878.9M | ||
| Q2 24 | $603.4M | $905.4M | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $4.9B | $2.5B | ||
| Q3 25 | $5.0B | $2.4B | ||
| Q2 25 | $5.1B | $2.5B | ||
| Q1 25 | $5.1B | $2.5B | ||
| Q4 24 | $5.2B | $2.5B | ||
| Q3 24 | $5.3B | $2.5B | ||
| Q2 24 | $5.7B | $2.5B | ||
| Q1 24 | $6.4B | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | 304.87× | 1.49× | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | $93.6M |
| Free Cash FlowOCF − Capex | $36.4M | $87.2M |
| FCF MarginFCF / Revenue | 14.8% | 25.7% |
| Capex IntensityCapex / Revenue | 12.1% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $93.6M | ||
| Q3 25 | $19.9M | $111.3M | ||
| Q2 25 | $61.2M | $17.4M | ||
| Q1 25 | $-30.1M | $116.6M | ||
| Q4 24 | $-33.4M | $43.8M | ||
| Q3 24 | $72.8M | $48.8M | ||
| Q2 24 | $18.5M | $-27.4M | ||
| Q1 24 | $49.7M | — |
| Q4 25 | $36.4M | $87.2M | ||
| Q3 25 | $-16.3M | $106.3M | ||
| Q2 25 | $36.6M | $13.6M | ||
| Q1 25 | $-68.9M | $100.9M | ||
| Q4 24 | $-63.8M | $35.2M | ||
| Q3 24 | $41.1M | $39.4M | ||
| Q2 24 | $-7.0M | $-33.1M | ||
| Q1 24 | $19.2M | — |
| Q4 25 | 14.8% | 25.7% | ||
| Q3 25 | -6.6% | 32.5% | ||
| Q2 25 | 15.2% | 4.2% | ||
| Q1 25 | -29.8% | 30.5% | ||
| Q4 24 | -27.5% | 10.1% | ||
| Q3 24 | 17.8% | 11.4% | ||
| Q2 24 | -3.0% | -9.8% | ||
| Q1 24 | 8.2% | — |
| Q4 25 | 12.1% | 1.9% | ||
| Q3 25 | 14.7% | 1.5% | ||
| Q2 25 | 10.2% | 1.2% | ||
| Q1 25 | 16.8% | 4.7% | ||
| Q4 24 | 13.1% | 2.5% | ||
| Q3 24 | 13.8% | 2.7% | ||
| Q2 24 | 10.9% | 1.7% | ||
| Q1 24 | 13.0% | — |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTEV
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
